Carlos Henrique Dos Anjos

7PUBLICATIONS
80CO-AUTHORS
Lexicography and semanticsPredictive and prognostic markersCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Jan 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Ivan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira

|Oct 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Carlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira

|Jul 15, 2025
Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer.

Gabriela D A Guardia, Carlos H Dos Anjos, Aline Rangel-Pozzo

|Jul 22, 2024
Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors.

Reitan Ribeiro, Filomena Marino Carvalho, Glauco Baiocchi

Pageof 2